Alto Neuroscience acquires two dopamine agonist candidates for TRD and Parkinson's

Alto Neuroscience, Inc.

Alto paid $1.75M cash plus $1.2M expense reimbursement upfront, with up to $71.5M in milestone payments ($41M commercial).
Acquired CTC-501 (renamed ALTO-207) for treatment-resistant depression and CTC-413 (ALTO-208) for Parkinson's disease.
Phase 2a of CTC-501 met primary endpoint; patients reached mean 4.1 mg/day, 67% achieved 5 mg, MADRS improvement d=1.1 (p=0.025).
Alto expects to initiate a potentially pivotal Phase 2b trial for ALTO-207 by mid-2026, with topline data in 2027.
Cash guidance unchanged; current cash expected to fund operations into 2028 through at least five planned clinical readouts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.